Current Immunotherapeutic Strategies for Central Nervous System Tumors
- 1 October 2007
- journal article
- review article
- Published by Elsevier in Surgical Oncology Clinics of North America
- Vol. 16 (4) , 987-1004
- https://doi.org/10.1016/j.soc.2007.07.003
Abstract
No abstract availableKeywords
This publication has 87 references indexed in Scilit:
- Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus—mediated interleukin-12Journal of Neurosurgery, 2002
- A phase III study of radiation therapy plus carmustine with or without recombinant interferon-? in the treatment of patients with newly diagnosed high-grade gliomaCancer, 2001
- Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor modelsGene Therapy, 1999
- Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukinsGene Therapy, 1998
- Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cellsJournal of Neurosurgery, 1992
- The Dendritic Cell System and its Role in ImmunogenicityAnnual Review of Immunology, 1991
- T‐lymphocyte entry into the central nervous systemJournal of Neuroscience Research, 1991
- Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor β2Journal of Neurosurgery, 1989
- Lymph-Borne Dendritic Leucocytes do Not Recirculate, but Enter the Lymph Node Paracortex to Become Interdigitating CellsScandinavian Journal of Immunology, 1988
- Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth.The Journal of Experimental Medicine, 1986